Company Monitoring Page for Takeda

latest headlines for company on cafepharma

Takeda mulling sale of emerging market drugs – report
Pharmaforum
Tue, 01/22/19 - 11:39 am
Tags:
Takeda, Shire, M&A, emerging markets
Takeda’s Shire takeover could herald new era of pharma M&A
Pharmaforum
Wed, 01/9/19 - 09:18 am
Tags:
M&A, Takeda, Shire, taxes, Pfizer
With mega merger season in full swing, Takeda officially swallows Shire
Endpoints
Tue, 01/8/19 - 07:09 pm
Tags:
Takeda, Shire, M&A
Takeda to keep consumer business, looks outside Japan for selloffs instead: CEO
Fierce Pharma
Tue, 01/8/19 - 09:14 am
Tags:
Takeda, Japan, consumer health, Christophe Weber
Takeda builds arsenal for immuno-oncology research, creates cell therapy group
Endpoints
Thu, 01/3/19 - 11:43 pm
Tags:
Takeda, immuno-oncology, cell therapy, Shire
New Class of Breast Cancer Drugs Could Help Treat Toughest Lung Cancer Cases
BioSpace
Fri, 12/28/18 - 01:30 pm
Tags:
breast cancer, lung cancer, AstraZeneca, Tagrisso, Novartis, Gleevec, Tasigna, Bristol-Myers Squibb, Sprycel, Pfizer, Bosulif, Takeda, Iclusig
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
Fri, 12/21/18 - 12:10 pm
Tags:
clinical trials, Takeda, Zinfandel Pharmaceuticals, pioglitazone, Alzheimer's disease, Boehringer Ingelheim, BI 409306, Merck, verubecestat, Celgene, MS, ozanimod, Incyte, ID01, melanoma, vTv Therapeutics, azeliragon, Roche, Tecentriq, Exelixis, colorectal cancer, JNJ, atabacestat, Sareptat Therapeutics, DMD, Exondys 51, Alkermes, ALKS-5461, clinical depression
Shire gears up to battle Allergan's Linzess with new constipation drug Motegrity
Fierce Pharma
Wed, 12/19/18 - 12:25 am
Tags:
Takeda, Shire, Allergan, chronic idiopathic constipation, Motegrity
Eisai, Takeda and GARDP hunt for new antibiotics
Pharmaforum
Wed, 12/12/18 - 09:54 am
Tags:
Eisai, Takeda, GARDP, antibiotics, R&D
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
Mon, 12/10/18 - 07:07 pm
Tags:
clinical trials, Multiple Myeloma, adaptive trial design, AbbVie, Celgene, Eli Lilly, Genentech, Janssen, Takeda
What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs
Endpoints
Wed, 12/5/18 - 11:32 am
Tags:
Takeda, Gilead Sciences, Martin Shkreli, drug pricing
A last-ditch effort to derail Takeda’s $62B Shire buyout goes down in flames
Endpoints
Wed, 12/5/18 - 09:46 am
Tags:
Takeda, Shire, M&A
Takeda Acquisition Of Shire May Bode Well For R&D Staff
Forbes
Mon, 12/3/18 - 10:05 am
Tags:
Shire, Takeda, R&D, M&A
Takeda ready to dismiss assets for a total $10bn
GoinPharma
Sun, 12/2/18 - 12:35 pm
Tags:
Takeda, Shire, M&A
ASH: Takeda maintenance data sets up Ninlaro for new myeloma nod
Fierce Pharma
Sun, 12/2/18 - 12:34 pm
Tags:
ASH2018, Takeda, Ninlaro, Multiple Myeloma
Takeda could rack up $10B in selloffs after controversial Shire buyout: report
Fierce Pharma
Fri, 11/30/18 - 12:22 pm
Tags:
Takeda, Shire, M&A, shareholders
A Small Group of Pharma Companies Is Making the Bulk of Medicines Necessary for Developing Countries
BioSpace
Fri, 11/23/18 - 01:08 pm
Tags:
GSK, JNJ, Novartis, Merck KGaA, Sanofi, Takeda, developing countries
Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains
Endpoints
Tue, 11/20/18 - 12:17 pm
Tags:
Takeda, shareholders, Japan, M&A, Shire, Europe
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
Mon, 11/19/18 - 11:29 am
Tags:
cancer, breast cancer, lung cancer, drug approvals, AstraZeneca, Takeda, Ariad Pharmaceuticals, Merck, Pfizer, Novartis, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Puma Biotechnology, Mylan, Genentech
Takeda investors mount last-minute effort to stymie Shire deal: FT
Fierce Pharma
Fri, 11/16/18 - 07:50 pm
Tags:
Takeda, Shire, shareholders, M&A

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.